Abcuro gets $66M for Phase 3 in muscle-weakening condition
Endpoints News reports Abcuro raised $66M to advance its Phase 3 program in a muscle-weakening condition.
Abcuro
Private
Abcuro is a clinical-stage biopharmaceutical company developing first-in-class immunotherapies targeting immunomodulatory receptors for autoimmune diseases and cancer, including a late-stage program for inclusion body myositis.
Company Info
Sector:Immunotherapy / Autoimmune
Headquarters:Newton, Massachusetts, USA
Founded:2015
Website:abcuro.com/